Amgen's Xgeva delays prostate cancer bone pain
(Reuters):
"Reuters - A clinical trial of Amgen Inc's bone drug, Xgeva, found that it can significantly delay the time it takes for prostate cancer to cause bone pain -- a finding the company believes will help boost the drug's market potential."
The drug is currently approved as a treatment for reducing fractures and other bone problems in certain cancer patients. It is also sold under the brand name Prolia as a treatment for osteoporosis.
